Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

FDA Approves Linvoseltamab for Relapsed/Refractory Multiple Myeloma

July 2nd 2025

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for use in patients with relapsed/refractory multiple myeloma.

CHMP Provides Positive Opinion for MRD Negativity as an End Point for Regulatory Myeloma Clinical Trials

July 2nd 2025

The EMA’s CHMP has issued a positive opinion for the use of MRD-negative CR as an end point for regulatory clinical trials for patients with myeloma.

Clinical "Gray Areas" Persist Amid Evolving Multiple Myeloma Treatment Strategies

July 2nd 2025

Ajai Chari, MD, expands on areas of uncertainty in multiple myeloma after his presentation at the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Approaches to Risk Stratification, Timing of Treatment Initiation Pose Challenges in Smoldering Myeloma

June 30th 2025

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

FDA Removes REMS Programs for All Currently Approved CD19- and BCMA-Directed CAR T-Cell Therapies in Hematologic Malignancies

June 30th 2025

The FDA has eliminated REMS programs for BCMA- and CD19-directed autologous CAR T-cell therapies approved for multiple myeloma and select types of lymphoma/leukemia.

The OncFive: Top Oncology Articles for the Week of 6/22

June 28th 2025

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

FDA Approves Changes to Monitoring Requirements, Removal of REMS Programs for Liso-Cel and Ide-Cel in B-Cell Malignancies

June 27th 2025

The FDA updated the labels for liso-cel and ide-cel to reduce monitoring select requirements and remove REMS programs for the CAR T-cell therapies.

JNJ-5322 Demonstrates Preliminary Efficacy and Is Safe in R/R Multiple Myeloma

June 26th 2025

The trispecific antibody JNJ-5322 showed preliminary efficacy and safety signals in BCMA- and GPRC5D-naive relapsed/refractory myeloma.

CHMP Recommends Isatuximab Plus VRd for Transplant-Eligible, Newly Diagnosed Myeloma

June 23rd 2025

CHMP issues positive opinion for isatuximab plus VRd in transplant-eligible, newly diagnosed multiple myeloma.

Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma

June 23rd 2025

Surbhi Sidana, MD, highlighted the continued efficacy of cilta-cel in patients with relapsed/refractory multiple myeloma, according to an ITT analysis.

Five Under 5: Top Oncology Videos for the Week of 6/15

June 22nd 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Dr van de Donk on Initial Safety and Efficacy Findings From the First-In-Human Study of JNJ-5322 in R/R Multiple Myeloma

June 20th 2025

Niels van de Donk, MD, discusses initial safety and efficacy findings from the first-in-human study of JNJ-5322 in relapsed or refractory multiple myeloma.

Subcutaneous Daratumumab Approaches EU Approval in High-Risk Smoldering Myeloma

June 20th 2025

The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.

Dr Landgren on the Efficacy of Dara-KRd in Newly Diagnosed Myeloma Regardless of Transplant Eligibility

June 18th 2025

C. Ola Landgren, MD, PhD, discussed the benefit of Dara-KRd in patients with multiple myeloma stratified by transplant eligibility, risk, and age.

Dr Lin on the Rationale for Evaluating Cilta-Cel–Associated Late-Onset Toxicities in Myeloma

June 18th 2025

Yi Lin, MD, PhD, discusses the rationale for evaluating the onset of delayed toxicities following cilta-cel infusion in patients with multiple myeloma.

Hematologists Highlight Notable Insights From the 2025 EHA Congress

June 18th 2025

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Dr Krishnan on the Potential Clinical Impact of Trispecific Antibodies in R/R Multiple Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses the potential clinical impact of trispecific antibodies in the management of relapsed/refractory multiple myeloma.